Several recent studies reported that mental disorders particularly schizophrenia increase the risks of severity and mortality following infection with SARS-CoV-2 [1]. The French High Authority of Health updated its recommendations and added people with psychiatric disorders among the priority audiences of the French vaccine strategy [2]. On March 13, 2021, Tunisia inaugurated its vaccination campaign against COVID-19 by launching the Evax.tn vaccination platform [3]. We carried out a study between April and May 2021 to assess the adherence of Tunisian patients with schizophrenia to the vaccine and to examine the impact of the psychotic symptoms on the vaccine decision. A total of 112 patients were included. The participants were predominantly males with a sex ratio of 2.29. The mean age was 47 ± 57 years. Twenty-four percent of patients had risk factors for severe cases of COVID-19.
展开▼
